Northland Capital Markets Upgrades Protagonist Therapeutics (PTGX) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Nasdaq slides over 1% as Alphabet results revive AI spending fears
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts PTGX Hot Sheet
Price: $145.72 +2.52%
Rating Summary:
21 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 22 | New: 16
Rating Summary:
21 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 22 | New: 16
Join SI Premium – FREE
Northland Capital Markets analyst Tim Chiang upgraded Protagonist Therapeutics (NASDAQ: PTGX) from Market Perform to Outperform with a price target of $40.00 (from $25.00).
For an analyst ratings summary and ratings history on Protagonist Therapeutics click here. For more ratings news on Protagonist Therapeutics click here.
Shares of Protagonist Therapeutics closed at $18.24 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Exlservice (EXLS) PT Raised to $48 at Stifel
- Porch Group Inc. (PRCH) PT Raised to $30 at StoneX
- Alphabet (GOOGL) PT Lowered to $332 at UBS
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
